Odyssey Therapeutics, Inc.

ODTX

$26.90

+1.89%

2026-09-04 10:31:46 EDT+$0.50

Healthcare

Biotechnology

NASDAQ

Active Trading

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse ...

Price Action of ODTX

$26.90

+1.89%+$0.50

High—

Low—

52W High-3.9%

Rel. vol—

Interval

Range56m

Volume—SMA5SMA10

—

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021 by Dr. Gary D. Glick, a chemist and serial biotech entrepreneur. The company is dedicated to discovering and developing next-generation precision medicines for patients with autoimmune and inflammatory diseases, as well as oncology. Its pipeline ...Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021 by Dr. Gary D. Glick, a chemist and serial biotech entrepreneur. The company is dedicated to discovering and developing next-generation precision medicines for patients with autoimmune and inflammatory diseases, as well as oncology. Its pipeline features several key drug candidates: OD-001, an oral small molecule RIPK2 inhibitor in Phase 2a for ulcerative colitis; OD-002, an oral SLC15A4 inhibitor targeting TLR7/8/9-mediated IRF5 activation; OD-003, a protein therapeutic agonizing TNFR2 on T regulatory cells; and additional assets including a bispecific TSLP/IL-33 antagonist, an IRAK4 scaffolding inhibitor, and a small molecule IRF5 inhibitor. Financially, the company has a market cap of approximately $640 million, with no revenue yet (pre-revenue), reflected in negative margins and cash flow. It has a strong current ratio of 7.2 and cash per share of $6.58, indicating a solid liquidity position for a clinical-stage firm. The company went public in May 2026 on NASDAQ, after a prior IPO withdrawal and subsequent renewal, indicating active efforts to access capital markets. Key financial metrics show heavy investment in R&D (R&D-to-revenue ratio of 42.5) and SG&A, typical for a biotech. Leadership includes founder and CEO Dr. Gary D. Glick, with a board chaired by Dr. Jeff Leiden. The company's vision is to transform the standard of care for immunology patients, leveraging a scalable drug development model.ExpandCollapse

Founded

2021

Employees

100

CEO

Gary D. Glick

Full Name

Odyssey Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

177.71%

Market Cap

$1.29B

Current Ratio

11.36

WACC

11.03%

ROIC

-27.64%

Contact Information

https://odysseytx.com

(617) 865-9628

51 Sleeper Street, Boston, MA 02210

Key Metrics of ODTX

Snapshot

Latest / TTM · 2 periods

Market Cap

$1.29B

ROCE

-20.9%

EV / EBITDA

-13.91x

+45.3% YoY

FCF Yield

-5.9%

+23.0% YoY

Cash Conversion Cycle

0.0d

Current Ratio

11.36

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of ODTX

Profitability trend

Latest / TTM · 2 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-10.55x

n/a

Debt / Equity

0.06

n/a

Current Ratio

11.36

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ODTX

Upcoming

Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-5.89 · Revenue $2.98M · 5 analysts
Dec 31, 2027
FY2027 · Estimated annual results
Est. EPS $-4.87 · Revenue $2.98M · 5 analysts
Sep 30, 2028
Q3 FY2028 · Estimated results
Est. EPS $-1.05 · Revenue $0.00 · 2 analysts
Dec 30, 2028
Q4 FY2028 · Estimated results
Est. EPS $-1.09 · Revenue $0.00 · 2 analysts

Recent history

Jun 30, 2026
Q2 FY2026 · Results reported
EPS $-1.74 · Revenue $0.00
Jun 23, 2026
8-K · SEC filing
View filing
Jun 17, 2026
Q1 FY2026 · Results reported
EPS $-0.81 · Revenue $0.00
View filing
May 11, 2026
8-K · SEC filing
View filing
May 8, 2026
IPO
Dec 31, 2025
FY2025 · Annual results
EPS $-5.39 · Revenue $2.98M

Financial Statements of ODTX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$3.0M	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-148.6M	—	-38.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+100.0%	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-5415.2%	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-4994.9%	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-130.7M	—	+15.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-4391.8%	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-5.6%	—	+218.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	7.20x	—	+36.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$269.8M	—	+111.2%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-5.39 vs -42.60	+87.3%	-1.74 vs -1.05	-66.1%
Revenue Surprise	$3.0M vs $3.0M	0.0%	—	—

Leadership Team of ODTX

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Jason Haas	Chief Financial Officer	USD 702,500	Male	1968	Active
Gary D. Glick	Founder, President, CEO & Director	USD 558,900	—	1962	Active
Collin Todd	Senior Vice President of Strategy & Business Development	USD 544,900	Male	1992	Active
Eicke Latz	Scientific Co-Founder	—	—	—	Active
Joseph McDonald	Chief Data Officer	—	—	—	Active
Natalie Dales	Chief of Research Operations & Portfolio Strategy	—	—	1970	Active
Jolie Siegel	Executive VP, General Counsel & Secretary	—	Female	1977	Active
Felix Meissner	Scientific Co-Founder	—	—	—	Active
Florian.I Schmidt	Scientific Co-Founder	—	—	—	Active
Kim Lewis	Scientific Co-Founder	—	—	—	Active

Recent News of ODTX

GlobeNewsWire8/26/2026Neutral

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team will participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference Conference Dates: September 9-11, 2026 Location: New York, NY Fireside Chat: September 9th at 8:35AM ET Morgan Stanley 24th Annual Global Healthcare Conference Conference Dates: September 14-16, 2026 Location: New York, NY Fireside Chat: September 14th at 10:45AM ET H.C. Wainwright 28th Annual Global Investment Conference Conference Dates: September 14-16, 2026 Location: New York, NY Fireside Chat: September 15th at 1:00PM ET Where available, live webcasts will be available under “News and Events” in the Investors section of the Company's website at www.odysseytx.com.

GuruFocus8/6/2026Neutral

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire

PRNewsWire8/6/2026Neutral

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets.

GlobeNewsWire8/4/2026Neutral

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial of OD-001 expected to initiate in 2H 2026 Cash on hand as of June 30, 2026 of $433.1M expected to fund operations into the second half of 2028 BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the second quarter ended June 30, 2026 and provided an update on recent progress and anticipated milestones. “Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,” said Gary D.

GlobeNewsWire6/17/2026Neutral

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the first quarter ended March 31, 2026 and highlighted progress across its clinical and preclinical portfolio. “During the quarter, we continued to build meaningful momentum and made significant progress across our portfolio, including delivering clinical proof-of-concept for our oral, small molecule, RIPK2 scaffolding inhibitor, OD-001, in moderate-to-severe ulcerative colitis,” said Gary D.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Odyssey Therapeutics, Inc.

Contact Information

Upcoming

FY2026 · Estimated annual results

FY2027 · Estimated annual results

Q3 FY2028 · Estimated results

Q4 FY2028 · Estimated results

Recent history

Q2 FY2026 · Results reported

8-K · SEC filing

Q1 FY2026 · Results reported

8-K · SEC filing

IPO

FY2025 · Annual results

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Upcoming

FY2026 · Estimated annual results

FY2027 · Estimated annual results

Q3 FY2028 · Estimated results

Q4 FY2028 · Estimated results

Recent history

Q2 FY2026 · Results reported

8-K · SEC filing

Q1 FY2026 · Results reported

8-K · SEC filing

IPO

FY2025 · Annual results

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update